Wanbury Q1 FY27: Revenue ₹164.58 Cr, PAT ₹21.70 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹166Cr
- +1.8% YoY
- +0.6% QoQ
- Net profit
- ₹3Cr
- −76.9% YoY
- −86.4% QoQ
- Margin
- 10%
- −5 pp YoY
- −8 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Wanbury Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4FY26 Revenue from Operations: ₹164.58 Crore - Year-on-Year (YoY) change: +1% - Q4FY26 API Revenue: ₹144 Crore - YoY change: -4% - FY26 Total Revenue from Operations: ₹650.26 Crore - YoY change: +8% (from ₹599.51 Crore in FY25) - FY26 API Revenue: ₹574 Crore - YoY growth: 8% - FY26 Formulations Revenue: ₹76 Crore - Management Commentary notes a revenue decline in Q4 due to West Asia crisis impacting API exports in March but states growth expected from new product launches in Q4. EBITDA for Q4FY26: ₹30.06 Crore, with a year-on-year (YoY) growth of 12% - EBITDA Margin for Q4FY26: 18.3%, up by 173 basis points (BPS) YoY - Profit After Tax (PAT) for Q4FY26: ₹21.70 Crore, with YoY growth of 38% - PAT Margin for Q4FY26: 13.19%, up by 349 BPS YoY
From Wanbury Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q4FY26 Revenue from Operations: ₹164.58 Crore
- Year-on-Year (YoY) change: +1%
- Q4FY26 API Revenue: ₹144 Crore
- YoY change: -4%
- FY26 Total Revenue from Operations: ₹650.26 Crore
- YoY change: +8% (from ₹599.51 Crore in FY25)
- FY26 API Revenue: ₹574 Crore
- YoY growth: 8%
- FY26 Formulations Revenue: ₹76 Crore
- Management Commentary notes a revenue decline in Q4 due to West Asia crisis impacting API exports in March but states growth expected from new product launches in Q4.
- Outlook:
2 more points from Wanbury Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Wanbury Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Upcoming 1.5 MW solar energy project at Satara site to meet 70% of Patalganga site’s energy needs through renewable energy (Page 12).
- Brownfield expansion planned for operational scale-up and margin expansion (Page 5).
- Future reactor capacity potential at existing sites: 600 KL (current capacity 500 KL) indicating planned capacity expansion (Page 15).
2 more points from Wanbury Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wanbury Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Wanbury Ltd said on order book & pipeline — free account, 30 seconds.
Wanbury Ltd — Quarterly revenue & net profit
Wanbury Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 166 | 163 | +1.8% | 165 | +0.6% |
| Operating profit (EBITDA) | 16 | 24 | -33.3% | 30 | -46.7% |
| Operating margin | 10% | 15% | -5 pp | 18% | -8 pp |
| Profit before tax | 5 | 14 | -64.3% | 15 | -66.7% |
| Net profit (PAT) | 3 | 13 | -76.9% | 22 | -86.4% |
| EPS (₹) | 0.93 | 4.10 | -77.3% | 6.21 | -85% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹183 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wanbury's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Wanbury Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Wanbury Ltd Q1 FY27 results?
Q4FY26 Revenue from Operations: ₹164.58 Crore - Year-on-Year (YoY) change: +1% - Q4FY26 API Revenue: ₹144 Crore - YoY change: -4% - FY26 Total Revenue from Operations: ₹650.26 Crore - YoY change: +8% (from ₹599.51 Crore in FY25) - FY26 API Revenue: ₹574 Crore - YoY growth: 8% - FY26 Formulations Revenue: ₹76 Crore - Management Commentary notes a revenue decline in Q4 due to West Asia crisis impacting API exports in March but states growth expected from new product launches in Q4. EBITDA for Q4FY26: ₹30.06 Crore, with a year-on-year (YoY) growth of 12% - EBITDA Margin for Q4FY26: 18.3%, up by 173 basis points (BPS) YoY - Profit After Tax (PAT) for Q4FY26: ₹21.70 Crore, with YoY growth of 38% - PAT Margin for Q4FY26: 13.19%, up by 349 BPS YoY
What is Wanbury Ltd share price analysis?
Wanbury Ltd currently shows a neutral. The stock trades at a P/E of 13.1 with a market cap of ₹779 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wanbury Ltd planning capital expenditure?
Upcoming 1.5 MW solar energy project at Satara site to meet 70% of Patalganga site’s energy needs through renewable energy (Page 12).
Keep Wanbury Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
